MRK Looking At Acquisitions to Boost Their Drug Business
Get Alerts MRK Hot Sheet
Price: $130.72 +2.93%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +47.9%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +47.9%
Join SI Premium – FREE
According to reports from Bloomberg, Merck & Co. Inc. (NYSE: MRK) said in an interview they plan on making acquisitions to boost their drug business. A look at some companies that MRK could acquire based on ongoning relationships or market chatter: Geron Corporation (Nasdaq: GERN), MRK owns stake; Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) alliance with MRK; Vical Incorporated (Nasdaq: VICL) alliance with MRK; Orchid Cellmark Inc. (Nasdaq: ORCH) alliance with MRK; Atherogenics Inc. (Nasdaq: AGIX), BusinessWeek highlighted the stock as a takeover target for MRK; FoxHollow Technologies (Nasdaq: FOXH) agreement with MRK; DOV Pharmaceutical, Inc (Nasdaq: DOVP) agreement with MRK; Metabasis Therapeutics, Inc. (Nasdaq: MBRX) agreement with MRK; XOMA Ltd. (Nasdaq: XOMA) agreement with MRK; Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) agreement with MRK; Allergan Inc. (NYSE: AGN) seen as takeover target in space; Millennium Pharmaceuticals Inc. (Nasdaq: MLNM) seen as takeover target in space; Cephalon (Nasdaq: CEPH) seen as takeover target in space. NOTE: The relationships mentioned above are based past news releases and disclosures from either company over the past 9 months and may not be ongoing.
You May Also Be Interested In
- Paramount Global (PARA) and Skydance are closer to a merger - CNBC
- Exclusive-Anglo American does not find BHP $39 billion offer attractive
- Hawaiian Electric Industries (HE) Said To Weigh Sale Of American Savings Bank - Bloomberg
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!